Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

BACKGROUND: Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins have yet to be identified in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartmaier, R J, Trabucco, S E, Priedigkeit, N, Chung, J H, Parachoniak, C A, Vanden Borre, P, Morley, S, Rosenzweig, M, Gay, L M, Goldberg, M E, Suh, J, Ali, S M, Ross, J, Leyland-Jones, B, Young, B, Williams, C, Park, B, Tsai, M, Haley, B, Peguero, J, Callahan, R D, Sachelarie, I, Cho, J, Atkinson, J M, Bahreini, A, Nagle, A M, Puhalla, S L, Watters, R J, Erdogan-Yildirim, Z, Cao, L, Oesterreich, S, Mathew, A, Lucas, P C, Davidson, N E, Brufsky, A M, Frampton, G M, Stephens, P J, Chmielecki, J, Lee, A V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913625/
https://www.ncbi.nlm.nih.gov/pubmed/29360925
http://dx.doi.org/10.1093/annonc/mdy025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913625/
https://www.ncbi.nlm.nih.gov/pubmed/29360925
http://dx.doi.org/10.1093/annonc/mdy025

Ejemplares similares